CORONAVIRUS
Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strict guidelines to ensure the safety of all employees across the Chiesi Group in line with government policies and needs and following the WHO recommendations. We are committed to our focus on improving the quality of human life and put people at the center of our actions, to protect the health and wellbeing of our employees, patients and partners.
18
12/25
NEWS
MHRA Submission Marks New Step in Chiesi’s Carbon Minimal...
Parma, Italy – 18 December 2025   Chiesi announces the submission of the Carbon Minimal...
  • PRESS RELEASE
    Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with...
    The two studies presented at BTS demonstrated therapeutic equivalence and similar safety profiles of Chiesi’s...
© 2026 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: